Abstract
As the global threat of drug- and antibiotic-resistant bacteria continues to rise, new strategies are required to advance the drug discovery process. This work describes the construction of an array of Escherichia coli strains for use in whole-cell screens to identify new antimicrobial compounds. We used the recombination systems from bacteriophages λ and P1 to engineer each strain in the array for low-level expression of a single, essential gene product, thus making each strain hypersusceptible to specific inhibitors of that gene target. Screening of nine strains from the array in parallel against a large chemical library permitted identification of new inhibitors of bacterial growth. As an example of the target specificity of the approach, compounds identified in the whole-cell screen for MurA inhibitors were also found to block the biochemical function of the target when tested in vitro.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Monroe, S. & Polk, R. Antimicrobial use and bacterial resistance. Curr. Opin. Microbiol. 3, 496–501 (2000).
Silver, L.L. & Bostian, K.A. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 37, 377–383 (1993).
Davies, J.E. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Found. Symp. 207, 15–27 (1997).
Witte, W. Selective pressure by antibiotic use in livestock. Int. J. Antimicrob. Agents 16 Suppl 1, S19–24 (2000).
Ochman, H., Lawrence, J.G. & Groisman, E.A. Lateral gene transfer and the nature of bacterial innovation. Nature 405, 299–304 (2000).
Tsiodras, S. et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).
Pucci, M.J., Dougherty, T.J. & Barrett, J.F. Why are there no new antibiotics? Exp. Opin. Invest. Drugs 7, 1233–1235 (1998).
Pucci, M.J., Dougherty, T.J. & Barrett, J.F. Targets, targets everywhere—so, where are the new antibacterial drugs? Curr. Opin. Antiinfect. Invest. Drugs 2, 123–124 (2000).
Read, T.D., Gill, S.R., Tettelin, H. & Dougherty, B.A. Finding drug targets in microbial genomes. Drug Discov. Today 6, 887–892 (2001).
Arigoni, F. et al. A genome-based approach for the identification of essential bacterial genes. Nat. Biotechnol. 16, 851–856 (1998).
Wong, K.K. & Pompliano, D.L. in Resolving the antibiotic paradox: progress in drug design and resistance. (eds Rosen, B. & Mobashery, S.) 1–21 (Plenum Press, New York; 1999).
Murphy, K.C. Lambda Gam protein inhibits the helicase and chi-stimulated recombination activities of Escherichia coli RecBCD enzyme. J. Bacteriol. 173, 5808–5821 (1991).
Hoess, R.H., Ziese, M. & Sternberg, N. P1 site-specific recombination: nucleotide sequence of the recombining sites. Proc. Natl. Acad. Sci. USA 79, 3398–3402 (1982).
Guzman, L.M., Belin, D., Carson, M.J. & Beckwith, J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 177, 4121–4130 (1995).
Lopilato, J., Bortner, S. & Beckwith, J. Mutations in a new chromosomal gene of Escherichia coli K-12, pcnB, reduce plasmid copy number of pBR322 and its derivatives. Mol. Gen. Genet. 205, 285–290 (1986).
Abremski, K., Hoess, R. & Sternberg, N. Studies on the properties of P1 site-specific recombination: evidence for topologically unlinked products following recombination. Cell 32, 1301–1311 (1983).
Zhang, Y., Buchholz, F., Muyrers, J.P. & Stewart, A.F. A new logic for DNA engineering using recombination in Escherichia coli. Nat. Genet. 20, 123–128 (1998).
Kim, D.H. et al. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 35, 4923–4928 (1996).
Heath, R.J., Yu, Y.T., Shapiro, M.A., Olson, E. & Rock, C.O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273, 30316–30320 (1998).
Wolf, H., Chinali, G. & Parmeggiani, A. Kirromycin, an inhibitor of protein biosynthesis that acts on elongation factor Tu. Proc. Natl. Acad. Sci. USA 71, 4910–4914 (1974).
Bostian, K.A. & Schmidt, M.B. in Antibacterial therapy: achievements, problems, and future perspectives (eds Busse, W.D., Zeiler, H.J. & Labischinski, H.) 61–68 (Springer-Verlag, Berlin; 1997).
Schmid, M.B. Novel approaches to the discovery of antimicrobial agents. Curr. Opin. Chem. Biol. 2, 529–534 (1998).
Trias, J. & Yuan, Z. in Enzyme technologies for pharmaceutical and biotechnological applications (eds Kirst, H.A., Yeh, W.K. & Zmijewski, M.J.) 499–511 (Marcel-Dekker, New York; 2001).
Yu, D. et al. An efficient recombination system for chromosome engineering in Escherichia coli. Proc. Natl. Acad. Sci. USA 97, 5978–5983 (2000).
Murphy, K.C. Use of bacteriophage lambda recombination functions to promote gene replacement in Escherichia coli. J. Bacteriol. 180, 2063–2071 (1998).
Roberts, J. & Devoret, R. In Lambda II (eds Hendrix, R.W., Roberts, J.W., Stahl, F.W. & Weisberg, R.A.) 123–144 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1983).
Schleif, R. Regulation of the l-arabinose operon of Escherichia coli. Trends Genet. 16, 559–565 (2000).
Apfel, C.M. et al. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents. Chemother. 45, 1058–1064 (2001).
Chen, D.Z. et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39, 1256–1262 (2000).
Sambrook, J., Russel, D.W. & Sambrook, J. Molecular cloning: a laboratory manual, Edn. 3 (Cold Spring Harbor Laboratories, Cold Spring Harbor; NY, 2001).
Sternberg, N., Sauer, B., Hoess, R. & Abremski, K. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. J. Mol. Biol. 187, 197–212 (1986).
Miller, J.H. Experiments in molecular genetics (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1972).
Court, D. & Oppenheim, A.B. In Lambda II (eds Hendrix, R.W., Roberts, J.W., Stahl, F.W. & Weisberg, R.A.) 251–277 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1983).
Eliopoulous, G.M. & Moellering Jr., R.C. In Antibiotics in laboratory medicine (ed. Lorian, V.) 330–396 (Williams and Wilkins, Baltimore, MD; 1996).
Marquardt, J.L., Siegele, D.A., Kolter, R. & Walsh, C.T. Cloning and sequencing of Escherichia coli murZ and purification of its product, a UDP-N-acetylglucosamine enolpyruvyl transferase. J. Bacteriol. 174, 5748–5752 (1992).
Acknowledgements
We are grateful to Michael G. Kurilla for countless helpful insights, to Janet Kaczmarczyk and Jason Sparkowski for technical aid in the early phases of this work, to Don Court for strains, to Bob Weisberg for phage, and to Ron Hoess and Piet DiBoer for plasmids. This work was completed while the authors were employees of the DuPont Pharmaceuticals Company.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The work described in this manuscript was performed while the authors were all employees of the DuPont Pharmaceuticals Company. During the manuscript review period, DuPont Pharmaceuticals was purchased by, and became part of, Bristol-Myers Squibb. Many of the authors have since moved on to other opportunities. D.L.P. is currently employed by GlaxoSmithKline. J.A.M. is employed by Essential Therapeutics. A.A. is employed by Bristol-Myers Squibb. C.F.S. is a US Government employee. V.G.L. is employed by Centocor.
Rights and permissions
About this article
Cite this article
DeVito, J., Mills, J., Liu, V. et al. An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol 20, 478–483 (2002). https://doi.org/10.1038/nbt0502-478
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nbt0502-478
This article is cited by
-
Deep learning-driven prediction of drug mechanism of action from large-scale chemical-genetic interaction profiles
Journal of Cheminformatics (2022)
-
Low-cost anti-mycobacterial drug discovery using engineered E. coli
Nature Communications (2022)
-
Bioprospecting for Antibacterial Drugs: a Multidisciplinary Perspective on Natural Product Source Material, Bioassay Selection and Avoidable Pitfalls
Pharmaceutical Research (2020)
-
Antifungal and cytotoxicity activities of the fresh xylem sap of Hymenaea courbaril L. and its major constituent fisetin
BMC Complementary and Alternative Medicine (2014)
-
Tunable protein degradation in bacteria
Nature Biotechnology (2014)